桑加莫生物科学 SGMO 深 沪
等待开盘 11-15 09:30:00 美东时间
0.4447
-0.004
-1.00%
华盛通- 最 高0.46
- 今 开0.44
- 成交量 334.24万股
- 最 低 0.435
- 昨 收 0.4492
- 总市值 1.34亿
- 52周最高 2.84
- 市盈率 静 --
- 换手率 1.11%
- 52周最低 0.4111
- 委 比 33.33%
- 总股本 3.02亿
- 历史最高 27.50
- 量 比 0.78
- 振 幅 5.57%
- 历史最低 0.2911
- 每 手 1
- 风险率 0.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Barclays Downgrades Sangamo Therapeutics to Equal-Weight, Lowers Price Target to $1
Barclays analyst Gena Wang downgrades Sangamo Therapeutics (NASDAQ:SGMO) from Overweight to Equal-Weight and lowers the price target from $5 to $1.
11-07 20:24
电话会总结 ｜ Sangamo(SGMO)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Sangamo业绩会实录，我需要指出一个重要问题： **财务信息披露不足** 本次业绩会实录中**缺乏详细的财务业绩数据**。会议主要聚焦于临床试验进展、监管事务和业务发展，而未提供传统的财务报表数据。 ## 1. 财务业绩：- **营收(Revenue)**：未披露具体营收数据 - **利润率(Profit Margin)**：未披露毛利率或净利润率数据 - **净利润(Net Income)**：未披露净利润或亏损数据 - **现金流(Cash Flow)**：未披露经营性现金流或自由现金流数据 ## 2. 财务指标变化：- **现金及现
11-07 12:30
Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.
Sangamo Therapeutics shares are trading lower after the company reported worse-...
11-06 23:52
Sangamo Therapeutics Q3 EPS $(0.11) Misses $(0.01) Estimate, Sales $581.000K Miss $34.400M Estimate
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.01) by 1275 percent. This is a 375 percent decrease over earnings of $0.04 per share
11-06 21:02
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call
Sangamo Therapeutics, a genomic medicine company, has announced the release of its third quarter 2025 financial results and a conference call on November 6, 2025. The call, open to the public, will review financial results and provide business updates. Participants are advised to register via the provided link and join 10 minutes prior to the event. A live webcast will be available on the company's website, with a replay accessible afterward. The...
10-30 20:01
Sangamo Biosciences Granted Nasdaq Compliance Extension
Sangamo Biosciences ( ($SGMO) ) just unveiled an update. On October 29, 2025, S...
10-30 04:40
徘徊生死线上的Biotech，首席财务官辞职
近日，Sangamo Therapeutics的首席财务官Prathyusha Duraibabu通知公司，她决定辞去CFO职务，辞职将于2025年10月1日生...
09-23 12:03
